文献速递血液净化与透析

血液透析未诱导可检测的接触系统凝血激活

Hemodialysis Does Not Induce Detectable Activation of the Contact System of Coagulation.
PubMed 文献 · Kidney Int Rep · 2020-03-13

尽管使用全身抗凝,透析中TAT自30分钟后升高,而FXIIa、激肽释放酶和FXIa等接触系统标志物均无显著变化,提示常规血液透析诱导凝血激活但不伴可测量的接触系统激活。

要点

  • 血液透析患者基线TAT和PF1+2水平高于健康对照
  • 透析中TAT在30分钟后升高,三种透析膜均如此
  • FXIIa、激肽释放酶和FXIa在透析中均无显著变化

核心结论

  • 常规使用全身肝素抗凝的血液透析诱导凝血激活,但未诱导可检测的接触系统激活。

研究设计与样本

  • 在血泵启动前及启动后5、15、30、90、240分钟采集血样,检测凝血激活标志物。
  • 以20名健康志愿者血浆作为参考。

主要发现

  • 透析患者基线TAT中位数3.3(2.9-4.2)μg/l高于健康对照2.4(2.3-2.5)μg/l,P=0.0002。
  • 透析患者基线PF1+2中位数647(478-737)pmol/l高于健康对照138(125-254)pmol/l,P<0.0002。
  • 尽管使用全身抗凝,TAT在透析30分钟后进一步升高,t240中位数PP为9.0 μg/l、PMMA为5.5 μg/l、AN69ST为7.2 μg/l,均P<0.05 vs 基线。
  • 接触系统标志物FXIIa和激肽释放酶在透析患者与健康对照间无显著差异,基线FXIa在透析患者中显著低于健康对照(P=0.001)。
  • 所有接触系统标志物在三种透析膜透析期间均保持不变。

临床怎么用

  • 常规血液透析中凝血激活可能不主要通过接触系统途径,抗凝策略应针对其他凝血激活机制。
  • 当前时代透析膜下监测接触系统标志物对评估透析中凝血激活的临床价值有限。

局限性

  • 仅评估三种透析膜,不能外推至其他膜类型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Systemic anticoagulation is administered during hemodialysis to prevent clotting of the extracorporeal circuit. The role of contact system activation in thrombin generation during hemodialysis using current era dialyzer membranes is unknown. METHODS: We performed a single-center randomized crossover study. Ten patients treated with hemodialysis underwent 3 standardized hemodialysis sessions. For every patient, each session was performed with a different type of dialyzer membrane (polyphenylene [PP], polymethylmetacrylate [PMMA], polyethylenimine-coated polyacrylonitrile [AN69ST]). Blood samples were collected before and 5, 15, 30, 90, and 240 minutes after blood pump start to evaluate coagulation activation (thrombin-antithrombin complex [TAT], prothrombin fragment 1+2 [PF1+2], activated factor XII [FXIIa], kallikrein, activated factor XI [FXIa]). Plasma of healthy volunteers (n = 20) was used as a reference. RESULTS: Baseline TAT and PF1+2 levels were higher in hemodialysis patients compared to healthy controls (median [interquartile range] for TAT: 3.3 [2.9-4.2] vs. 2.4 [2.3-2.5] μg/l [P = 0.0002] and for PF1+2: 647 [478-737] vs. 138 [125-254] pmol/l [P < 0.0002]). Despite the use of systemic anticoagulation, TAT further increased during treatment, with the increase starting after 30 minutes (median TAT at t240: 9.0 μg/l (PP), 5.5 μg/l (PMMA), and 7.2 μg/l (AN69ST), all P < 0.05 vs. baseline). Contact system markers FXIIa and kallikrein did not differ significantly between dialysis patients and healthy controls, whereas baseline FXIa levels were significantly lower in dialysis patients compared to healthy controls (P = 0.001). Levels of all contact system markers remained unchanged during hemodialysis with all types of dialyzer membranes. CONCLUSION: Routine hemodialysis using systemic heparin anticoagulation induces coagulation activation without measurable contact system activation.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. François K, Orlando C, Jochmans K, et al. Hemodialysis Does Not Induce Detectable Activation of the Contact System of Coagulation. Kidney Int Rep. 2020. PMID: 32518865. doi:10.1016/j.ekir.2020.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。